



**To:** MaineCare Providers  
**From:** Anne-Marie Toderico, Director of Pharmacy  
**Date:** 10/06/2022  
**Re:** PDL Update for 10/7/2022

## MaineCare PDL Update for October 7, 2022

The following medication(s) have been recently added/changed to the MaineCare PDL as **non-preferred** and will require prior authorization:

- Alymsys
- Byooviz
- Chlorzoxazone 250mg
- Epsolay
- Igalmi
- Lyvispah
- Mounjaro
- Norliqva
- Quviviq
- Ranexa
- Tlando
- Vonjo
- Vtama
- Zaltrap

The following medication(s) have recently been added to the MaineCare PDL as **preferred** and will **not** require a prior authorization:

- Evoclin
- Paliperidone ER
- Ranolazine ER Tabs

The following medication(s) have recently been added to the MaineCare PDL as **non-preferred** with new PDL criteria:

- Adlarity: Approvals will require trials and failure or clinical rationale why preferred patches can't be used.
- Amvuttra: PA required for appropriate diagnosis.
- Aspuzyo: DDI: Concomitant use of Aspuzyo® Sprinkle with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir, is contraindicated.
- Camzyos: For the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. DDI: Concomitant use of Camzyos® with a moderate to strong CYP2C19 inhibitor or a strong CYP3A4 inhibitor is contraindicated.

The following medication(s) has miscellaneous criteria updates.

- Oxbryta is for the treatment of patients  $\geq 4$  years of age.